{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:27Z","timestamp":1791568827282,"version":"4.3.4"},"reference-count":92,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cpet.2024.03.004","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T05:13:16Z","timestamp":1713676396000},"page":"401-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-6901","authenticated-orcid":false,"given":"Simone","family":"Dalm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2834-5524","authenticated-orcid":false,"given":"Heying","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-5329","authenticated-orcid":false,"given":"Andrei","family":"Iagaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cpet.2024.03.004_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.004_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.004_bib3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpet.2024.03.004_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","article-title":"The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far","volume":"98-99","author":"Heynickx","year":"2021","journal-title":"Nucl Med Biol"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.004_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/BF02145873","article-title":"Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes","volume":"27","author":"Anastasi","year":"1971","journal-title":"Experientia"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib6","first-page":"5","article-title":"Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease","volume":"59","author":"Sunday","year":"1988","journal-title":"Lab Invest"},{"issue":"10","key":"10.1016\/j.cpet.2024.03.004_bib7","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.7150\/thno.14958","article-title":"Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist (68)Ga-RM2 and PET","volume":"6","author":"Stoykow","year":"2016","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.004_bib8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2967\/jnumed.114.153023","article-title":"In\u00a0vitro and in\u00a0vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer","volume":"56","author":"Dalm","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2024.03.004_bib9","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1210\/jc.2005-0964","article-title":"Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments","volume":"90","author":"Fleischmann","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1\u20133","key":"10.1016\/j.cpet.2024.03.004_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0167-0115(00)00114-2","article-title":"The presence of receptors for bombesin\/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers","volume":"90","author":"Sun","year":"2000","journal-title":"Regul Pept"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5858\/arpa.2012-0679-OA","article-title":"Gastrin-releasing peptide receptor expression in lung cancer","volume":"138","author":"Mattei","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.004_bib12","first-page":"G655","article-title":"Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans","volume":"276","author":"Carroll","year":"1999","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.cpet.2024.03.004_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00259-004-1476-2","article-title":"High expression of peptide receptors as a novel target in gastrointestinal stromal tumours","volume":"31","author":"Reubi","year":"2004","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2024.03.004_bib14","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/s00428-007-0443-2","article-title":"Peptide receptor expression in GEP-NET","volume":"451","author":"Reubi","year":"2007","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.004_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/pros.22743","article-title":"Early over-expression of GRP receptors in prostatic carcinogenesis","volume":"74","author":"Korner","year":"2014","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.004_bib16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/pros.21434","article-title":"Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates","volume":"72","author":"Beer","year":"2012","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.004_bib17","first-page":"1152","article-title":"Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation","volume":"59","author":"Markwalder","year":"1999","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.004_bib18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7150\/thno.7324","article-title":"Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men","volume":"4","author":"Wieser","year":"2014","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.004_bib19","first-page":"1139","article-title":"Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14)","volume":"8","author":"Reubi","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.004_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B","article-title":"Presence of receptors for bombesin\/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers","volume":"42","author":"Sun","year":"2000","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.004_bib21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00428-006-0265-7","article-title":"Immunohistochemical detection of bombesin receptor subtypes GRP-R and BRS-3 in human tumors using novel antipeptide antibodies","volume":"449","author":"Schulz","year":"2006","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.004_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4149\/neo_2012_029","article-title":"Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor betacx in human prostate carcinoma","volume":"59","author":"Nagasaki","year":"2012","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib23","first-page":"88","article-title":"Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts","volume":"48","author":"de Visser","year":"2007","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2024.03.004_bib24","doi-asserted-by":"crossref","first-page":"650249","DOI":"10.3389\/fonc.2021.650249","article-title":"Gastrin-releasing peptide receptor in low grade prostate cancer: can it Be a better predictor than prostate-specific membrane antigen?","volume":"11","author":"Faviana","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.004_bib25","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1002\/ijc.25000","article-title":"Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts","volume":"126","author":"Schroeder","year":"2010","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.cpet.2024.03.004_bib26","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pros.20957","article-title":"Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer","volume":"69","author":"Ananias","year":"2009","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13550-016-0175-x","article-title":"Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in\u00a0vivo targeting of receptor-expressing tumors","volume":"6","author":"Accardo","year":"2016","journal-title":"EJNMMI Res"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.004_bib28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2967\/jnumed.122.264448","article-title":"A\u00a0pilot study of (68)Ga-PSMA11 and (68)Ga-RM2 PET\/MRI for biopsy guidance in patients with suspected prostate cancer","volume":"64","author":"Duan","year":"2023","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2024.03.004_bib29","doi-asserted-by":"crossref","first-page":"1199432","DOI":"10.3389\/fonc.2023.1199432","article-title":"GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches","volume":"13","author":"Verhoeven","year":"2023","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.cpet.2024.03.004_bib30","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","article-title":"PSMA- and GRPR-targeted PET: results from 50 patients with biochemically recurrent prostate cancer","volume":"62","author":"Baratto","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.004_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2967\/jnumed.115.168393","article-title":"Pilot comparison of (6)(8)Ga-RM2 PET and (6)(8)Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer","volume":"57","author":"Minamimoto","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.004_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00501302","article-title":"Action of bombesin on the motility of the stomach","volume":"289","author":"Bertaccini","year":"1975","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"34","key":"10.1016\/j.cpet.2024.03.004_bib33","first-page":"221","article-title":"177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations","author":"Bodei","year":"2007","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.004_bib34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2967\/jnumed.107.045054","article-title":"Bombesin receptor antagonists may be preferable to agonists for tumor targeting","volume":"49","author":"Cescato","year":"2008","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.004_bib35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.nucmedbio.2005.05.005","article-title":"Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes","volume":"32","author":"Smith","year":"2005","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1102\/1470-7330.2006.0025","article-title":"Targeting prostate cancer with radiolabelled bombesins","volume":"6","author":"Maina","year":"2006","journal-title":"Cancer Imag"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.004_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cpet.2016.12.002","article-title":"From bench to bed: new gastrin-releasing peptide receptor-directed radioligands and their use in prostate cancer","volume":"12","author":"Maina","year":"2017","journal-title":"Pet Clin"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.004_bib38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ymeth.2009.04.002","article-title":"Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues","volume":"48","author":"Schroeder","year":"2009","journal-title":"Methods"},{"issue":"22","key":"10.1016\/j.cpet.2024.03.004_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225766","article-title":"Radiolabeled bombesin analogs","volume":"13","author":"Mansi","year":"2021","journal-title":"Cancers"},{"issue":"39","key":"10.1016\/j.cpet.2024.03.004_bib40","doi-asserted-by":"crossref","first-page":"36652","DOI":"10.1074\/jbc.M104566200","article-title":"Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor","volume":"276","author":"Tokita","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13550-023-01005-1","article-title":"The effects of novel macrocyclic chelates on the targeting properties of the (68)Ga-labeled Gastrin releasing peptide receptor antagonist RM2","volume":"13","author":"Wang","year":"2023","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41181-020-00115-8","article-title":"Effect of the versatile bifunctional chelator AAZTA(5) on the radiometal labelling properties and the in\u00a0vitro performance of a gastrin releasing peptide receptor antagonist","volume":"5","author":"Hofstetter","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.004_bib43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.hoc.2012.02.014","article-title":"mTOR signaling pathway and mTOR inhibitors in cancer therapy","volume":"26","author":"Gomez-Pinillos","year":"2012","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.cpet.2024.03.004_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.nucmedbio.2022.03.003","article-title":"Development and biodistribution studies of (77)As-labeled trithiol RM2 bioconjugates for prostate cancer: comparison of [(77)As]As-trithiol-Ser-Ser-RM2 vs. [(77)As]As-trithiol-Glu-Ser-RM2","volume":"108-109","author":"Ma","year":"2022","journal-title":"Nucl Med Biol"},{"issue":"9","key":"10.1016\/j.cpet.2024.03.004_bib45","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2967\/jnumed.121.263323","article-title":"Substitution of l-tryptophan by alpha-Methyl-l-Tryptophan in (177)Lu-RM2 results in (177)Lu-AMTG, a high-affinity gastrin-releasing peptide receptor ligand with improved in\u00a0vivo stability","volume":"63","author":"Gunther","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2024.03.004_bib46","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2967\/jnumed.123.265771","article-title":"Preclinical comparison of the (64)Cu- and (68)Ga-labeled GRPR-targeted compounds RM2 and AMTG, as well as first-in-humans [(68)Ga]Ga-AMTG PET\/CT","volume":"64","author":"Koller","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2024.03.004_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/mtomcs\/mfac036","article-title":"Bioconjugated chelates based on (methylpyridinyl)tacn: synthesis, 64Cu labeling and in\u00a0vitro evaluation for prostate cancer targeting","volume":"14","author":"Marlin","year":"2022","journal-title":"Metallomics"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.004_bib48","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1021\/acs.jmedchem.7b01856","article-title":"Monomeric and dimeric (68)Ga-labeled bombesin analogues for positron emission tomography (PET) imaging of tumors expressing gastrin-releasing peptide receptors (GRPrs)","volume":"61","author":"Liolios","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cpet.2024.03.004_bib49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2191-219X-2-8","article-title":"Comparative study of 64Cu\/NOTA-[D-Tyr6,betaAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging","volume":"2","author":"Fournier","year":"2012","journal-title":"EJNMMI Res"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.004_bib50","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.3390\/molecules190710455","article-title":"The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin","volume":"19","author":"Varasteh","year":"2014","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.004_bib51","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1021\/bc300659k","article-title":"Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging","volume":"24","author":"Varasteh","year":"2013","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.cpet.2024.03.004_bib52","doi-asserted-by":"crossref","first-page":"6873684","DOI":"10.1155\/2017\/6873684","article-title":"High contrast PET imaging of GRPR expression in prostate cancer using cobalt-labeled bombesin antagonist RM26","volume":"2017","author":"Mitran","year":"2017","journal-title":"Contrast Media Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib53","doi-asserted-by":"crossref","first-page":"17086","DOI":"10.1038\/s41598-019-52914-y","article-title":"Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26","volume":"9","author":"Mitran","year":"2019","journal-title":"Sci Rep"},{"issue":"24","key":"10.1016\/j.cpet.2024.03.004_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245993","article-title":"Preclinical evaluation of the copper-64 labeled GRPR-antagonist RM26 in comparison with the cobalt-55 labeled counterpart for PET-imaging of prostate cancer","volume":"25","author":"Baun","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib55","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41598-021-82995-7","article-title":"(66)Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [(66)Ga]Ga-NOTA-PEG(2)-RM26","volume":"11","author":"Rinne","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.004_bib56","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3892\/ijo.2016.3429","article-title":"Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26","volume":"48","author":"Mitran","year":"2016","journal-title":"Int J Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.004_bib57","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/ijc.32401","article-title":"Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist (177) Lu-DOTAGA-PEG(2) -RM26","volume":"145","author":"Mitran","year":"2019","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.004_bib58","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/jlcr.3795","article-title":"Synthesis, radiolabeling, and evaluation of gastrin releasing peptide receptor antagonist (68) Ga-HBED-CC-RM26","volume":"62","author":"Satpati","year":"2019","journal-title":"J\u00a0Label Compd Radiopharm"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.004_bib59","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10967-018-6396-x","article-title":"Comparative cell uptake study of FITC-\/177Lu-labeled RM26 monomer, dimer and trimer on PC-3: improving binding affinity of gastrin releasing peptide receptor (GRPR) antagonist via bivalency\/trivalency","volume":"319","author":"Zhuo","year":"2019","journal-title":"J\u00a0Radioanal Nucl Chem"},{"issue":"6","key":"10.1016\/j.cpet.2024.03.004_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ph15060728","article-title":"Copper-67-Labeled bombesin peptide for targeted radionuclide therapy of prostate cancer","volume":"15","author":"Huynh","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.004_bib61","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1021\/jm00111a027","article-title":"Gastrin releasing peptide antagonists with improved potency and stability","volume":"34","author":"Heimbrook","year":"1991","journal-title":"J\u00a0Med Chem"},{"issue":"13","key":"10.1016\/j.cpet.2024.03.004_bib62","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1007\/s00259-022-05926-2","article-title":"Safety of [(177)Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity","volume":"49","author":"Ruigrok","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.cpet.2024.03.004_bib63","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-023-06364-4","article-title":"Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting","author":"Damiana","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.004_bib64","first-page":"749","article-title":"New antagonists of bombesin gastrin-releasing Peptide with C-terminal leu-psi-(ch2n)tac-nh2","volume":"7","author":"Reile","year":"1995","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib65","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1021\/acsomega.8b03293","article-title":"Positron emission tomography imaging of the gastrin-releasing peptide receptor with a novel bombesin analogue","volume":"4","author":"Lau","year":"2019","journal-title":"ACS Omega"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.004_bib66","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2967\/jnumed.120.257758","article-title":"A\u00a0radiotracer for molecular imaging and therapy of gastrin-releasing peptide receptor-positive prostate cancer","volume":"63","author":"Bratanovic","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.004_bib67","first-page":"27","article-title":"(68)Ga-Labeled [Leu(13)psiThz(14)]Bombesin(7-14) derivatives: promising GRPR-targeting PET tracers with low pancreas uptake","author":"Wang","year":"2022","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.cpet.2024.03.004_bib68","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.nucmedbio.2013.07.005","article-title":"Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer","volume":"40","author":"Richter","year":"2013","journal-title":"Nucl Med Biol"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.004_bib69","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/acs.molpharmaceut.5b00970","article-title":"Metabolically stabilized (68)Ga-NOTA-Bombesin for PET imaging of prostate cancer and influence of protease inhibitor Phosphoramidon","volume":"13","author":"Richter","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.cpet.2024.03.004_bib70","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nucmedbio.2020.10.005","article-title":"A\u00a0comparative PET imaging study of (44g)Sc- and (68)Ga-labeled bombesin antagonist BBN2 derivatives in breast and prostate cancer models","volume":"90-91","author":"Ferguson","year":"2020","journal-title":"Nucl Med Biol"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.004_bib71","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.122.263889","article-title":"Comparison of (68)Ga-PSMA-617 PET\/CT and (68)Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study","volume":"64","author":"Schollhammer","year":"2023","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2024.03.004_bib72","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.122.263971","article-title":"Correlation of (68)Ga-RM2 PET with post-surgery histopathology findings in patients with newly diagnosed intermediate- or high-risk prostate cancer","author":"Duan","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.004_bib73","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2967\/jnumed.117.197624","article-title":"Prospective evaluation of (68)Ga-RM2 PET\/MRI in patients with biochemical recurrence of prostate cancer and negative findings on conventional imaging","volume":"59","author":"Minamimoto","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.004_bib74","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.euo.2018.08.011","article-title":"Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography\/computed tomography imaging of newly diagnosed prostate cancer","volume":"2","author":"Touijer","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.cpet.2024.03.004_bib75","first-page":"S229","article-title":"Final analysis of a prospective, single-center, phase II\/III imaging trial of68Ga-RM2 PET\/MRI in patients with biochemical recurrence of prostate cancer","volume":"50","author":"Duan","year":"2023","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.cpet.2024.03.004_bib76","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-023-06385-z","article-title":"Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET","author":"Duan","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib77","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [(177)Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.cpet.2024.03.004_bib78","article-title":"The balance between the therapeutic efficacy and safety of [(177)Lu]Lu-NeoB in a preclinical prostate cancer model","author":"Verhoeven","year":"2023","journal-title":"Mol Imaging Biol"},{"issue":"3 Suppl","key":"10.1016\/j.cpet.2024.03.004_bib79","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cpet.2024.03.004_bib80","author":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.cpet.2024.03.004_bib81","doi-asserted-by":"crossref","first-page":"112503","DOI":"10.1118\/1.4824318","article-title":"An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT\/CT imaging","volume":"40","author":"Jackson","year":"2013","journal-title":"Med Phys"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.004_bib82","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.004_bib83","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.cpet.2024.03.004_bib84","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.004_bib85","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.004_bib86","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00259-018-4220-z","article-title":"Development and dosimetry of (203)Pb\/(212)Pb-labelled PSMA ligands: bringing \"the lead\" into PSMA-targeted alpha therapy?","volume":"46","author":"Dos Santos","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9","key":"10.1016\/j.cpet.2024.03.004_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091371","article-title":"Bispecific GRPR-antagonistic anti-PSMA\/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer","volume":"11","author":"Mitran","year":"2019","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.004_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11070358","article-title":"Synthesis and preclinical evaluation of radio-iodinated GRPR\/PSMA bispecific heterodimers for the theranostics application in prostate cancer","volume":"11","author":"Abouzayed","year":"2019","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.004_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12070614","article-title":"Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer-optimization of the affinity towards PSMA by linker modification in murine model","volume":"12","author":"Lundmark","year":"2020","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.004_bib90","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1021\/acs.jmedchem.0c01785","article-title":"Development of heterobivalent theranostic probes having high affinity\/selectivity for the GRPR\/PSMA","volume":"64","author":"Bandari","year":"2021","journal-title":"J\u00a0Med Chem"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.004_bib91","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/MNM.0000000000001520","article-title":"Radiosynthesis and biological evaluation of 18F-labeled bispecific heterodimer targeted dual gastrin-releasing peptide receptor and prostate-specific membrane antigen for prostate cancer imaging","volume":"43","author":"Ye","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.cpet.2024.03.004_bib92","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.nucmedbio.2021.03.005","article-title":"[(68)Ga]Ga-iPSMA-Lys(3)-Bombesin: biokinetics, dosimetry and first patient PET\/CT imaging","volume":"96-97","author":"Rivera-Bravo","year":"2021","journal-title":"Nucl Med Biol"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T20:39:22Z","timestamp":1720039162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859824000191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1556859824000191"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2024.03.004","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2024.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}